Skadden is advising Ionis Pharmaceuticals in its approximately $500 million acquisition of the remaining 24% stake in Akcea Therapeutics it does not already own, valuing Akcea at approximately $1.9 billion.
Skadden, Arps, Slate, Meagher & Flom LLP and Affiliates